Real-World data may unlock Pacritinib's true potential in myelofibrosis
NCT ID NCT07774455
First seen Aug 19, 2026 · Last updated Aug 19, 2026
Summary
This study looks back at medical records of adults with myelofibrosis who took pacritinib for at least a month. Researchers will track changes in spleen size, blood counts, symptoms, and survival to see how the drug performs in everyday practice. The goal is to understand real-world effectiveness beyond clinical trial settings.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- This study could reveal how well pacritinib works outside clinical trials, helping doctors make better treatment decisions for myelofibrosis patients.
- What could go wrong
- Because it's observational, it can't prove cause and effect. Results may be limited by incomplete records or the specific patient group studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS (MF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Dual-Action pill tame bone marrow tumors?
- Can a new daily pill shrink the spleen and ease myelofibrosis symptoms?
- New combo therapy hopes to shrink spleens and ease symptoms in Tough-to-Treat myelofibrosis
- New drug aims to stop anemia after stem cell transplants
- New drug ZE74-0282 targets rare blood cancers in early trial
- New combo therapy aims to shrink spleens in bone marrow cancer patients